First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset. Issue 12 (16th October 2020)

• Record Type: Journal Article
• Authors: Satouchi, Miyako; Nosaki, Kaname; Takahashi, Toshiaki; Nakagawa, Kazuhiko; Aoe, Keisuke; Kurata, Takayasu; Sekine, Akimasa; Horiike, Atsushi; Fukuhara, Tatsuro; Sugawara, Shunichi; Umemura, Shigeki; Saka, Hideo; Okamoto, Isamu; Yamamoto, Nobuyuki; Sakai, Hiroshi; Kishi, Kazuma; Katakami, Nobuyuki; Horinouchi, Hidehito; Hida, Toyoaki; Okamoto, Hiroaki; Atagi, Shinji; Ohira, Tatsuo; Han, Shi Rong; Noguchi, Kazuo; Ebiana, Victoria; Hotta, Katsuyuki
• Is Part Of: Cancer science. Volume 111:Issue 12(2020)
• Page Start: 4480
• Page End: 4489
• Publication Date: 2020-10-16
• Subjects: Japan -- non‐small‐cell lung carcinoma -- PD‐L1 protein -- pembrolizumab -- treatment outcome; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.14647
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐ small‐cell lung cancer without EGFR / ALK alterations and a programmed death ligand 1 (PD‐L1) tumor proportion score of 50% or higher evaluated clinical outcomes among patients enrolled in Japan. Treatment consisted of pembrolizumab 200 mg every 3 weeks (35 cycles) or platinum‐based chemotherapy (four to six cycles). The primary end‐point was progression‐free survival; secondary end‐points included overall survival and safety. Of 305 patients randomized in KEYNOTE‐024 overall, 40 patients were enrolled in Japan (all received treatment: pembrolizumab, n = 21; chemotherapy, n = 19). Median progression‐free survival was 41.4 (95% confidence interval [CI], 4.2‐42.5) months with pembrolizumab and 4.1 (95% CI, 2.8‐8.3) months with chemotherapy (hazard ratio [HR], 0.27 [95% CI, 0.11‐0.65]; one‐sided, nominal P = .001). Median overall survival was not reached (NR) (95% CI, 22.9‒NR) and 21.5 (95% CI, 5.2‐35.0) months, respectively (HR, 0.39 [95% CI, 0.17‐0.91]; one‐sided, nominal P = .012). Treatment‐related adverse events occurred in 21/21 (100%) pembrolizumab‐treated and 18/19 (95%) chemotherapy‐treated patients; eight patients (38%) and nine patients (47%), respectively, had grade 3‐5 events. Immune‐mediated adverse events and infusion reactions occurred in 11 pembrolizumab‐treated patients (52%) and four chemotherapy‐treated patients (21%), respectively; four patients (19%) and one patient (5%), respectively, had grade 3‐5 events. Consistent with results from KEYNOTE‐024 overall, first‐line pembrolizumab improved progression‐free survival and overall survival vs chemotherapy with manageable safety among Japanese patients with metastatic non‐ small‐cell lung cancer without EGFR / ALK alterations and a PD‐L1 tumor proportion score of 50% or higher. The trial is registered with Clinicaltrials.gov: NCT02142738. Abstract : This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a PD‐L1 tumor proportion score of 50% or higher evaluated clinical outcomes among patients enrolled in Japan. Consistent with results from KEYNOTE‐024 overall, first‐line pembrolizumab improved progression‐free survival and overall survival vs chemotherapy with manageable safety among 40 Japanese patients in the study.